Novel Lung Functional Imaging for Personalized Radiotherapy

Inclusion Criteria: * Primary lung cancer or metastatic disease to the lungs to be treated with either conventionally-fractionated radiotherapy (CFRT) or hypo-fractionated stereotactic ablative radiotherapy (SABR). * Age restriction and/or gender/ethnic restrictions: Patients must be ≥18 years of age. There are no gender or ethnic restrictions. * Concurrent chemotherapy is allowed, but not required. * Life expectancy with treatment should be ≥6 months in the estimation of the treating physicians. * Zubrod performance status ≤2 * Adequate marrow and hepatic function defined as Hgb ≥8; platelets ≥100k; ANC≥1500; LFTs ≤2x upper limit of normal and creatinine ≤1.3 or creatinine clearance of ≥50 * Patient must be able to provide study specific informed consent prior to study entry. Exclusion Criteria: * Prior radiotherapy for thoracic cancer or other malignancy leading to any overlap of planned radiotherapy fields. * For patients undergoing definitive CFRT, patients with distant metastatic disease are not eligible. * For patients undergoing SABR, both early stage primary lung cancer patients and those with limited metastatic disease to the lungs are eligible; however, patients with oligometastatic disease should have a controlled primary and no more than one other involved organ system. * Children (\<18 years of age), pregnant women, University of California employees or students, or prisoners will be excluded from this study.